Results of Operations and Financial Condition On August 10, 2026, CervoMed Inc. issued a press release announcing financial results as of and for the quarter ended June 30, 2026. A copy of that press release is attached hereto as Exhibit 99.1 and incorporated herein by reference. The information included in or incorporated by reference into this Item 2.02 (including Exhibit 99.1) is being furnished pursuant to

Unregistered Sales of Equity Securities. The information set forth in

Entry into a Material Definitive Agreement. On June 18, 2026, CervoMed Inc., a Delaware corporation (the “Company”), entered into a Securities Purchase Agreement (the “Purchase Agreement”) with the investors named therein (the “Investors”), pursuant to which the Company agreed to issue and sell, in a registered direct offering by the Company directly to the Investors (the “Offering”), 2,500,000 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (“Common Stock”), a…

Unregistered Sales of Equity Securities The disclosures set forth in

Entry into a Material Definitive Agreement On June 9, 2026, CervoMed Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain accredited investors named therein (each, an “Investor” and collectively, the “Investors”), for the private placement (the “Private Placement”) of an aggregate of 3,360,377 units (the “Units”), each Unit comprised of (i) (A) one share of the Company’s common stock, par value $0.001 per share (the “Common Stock”), or (B)…

Results of Operations and Financial Condition On May 18, 2026, CervoMed Inc. (the “Company,” “we” or “us”) issued a press release announcing financial results as of and for the three months ended December 31, 2026. A copy of that press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

Results of Operations and Financial Condition On March 17, 2026, CervoMed Inc. (the “Company,” “we” or “us”) issued a press release announcing financial results as of and for the quarter and full year ended December 31, 2025. A copy of that press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

Results of Operations and Financial Condition On November 10, 2025, CervoMed Inc. issued a press release announcing financial results as of and for the quarter ended September 30, 2025. A copy of that press release is attached hereto as Exhibit 99.1 and incorporated herein by reference. The information included in or incorporated by reference into this Item 2.02 (including Exhibit 99.1) is being furnished pursuant to

Director — David Quigley: David Quigley was appointed as a new director of the Company.

Results of Operations and Financial Condition On August 11, 2025, CervoMed Inc. issued a press release announcing financial results as of and for the quarter ended June 30, 2025. A copy of that press release is attached hereto as Exhibit 99.1 and incorporated herein by reference. The information included in or incorporated by reference into this Item 2.02 (including Exhibit 99.1) is being furnished pursuant to

Entry into a Material Definitive Agreement On May 12, 2025, CervoMed Inc. (the “Company”) entered into a sales agreement (the “Sales Agreement”) with Leerink Partners LLC (the “Sales Agent”), pursuant to which the Company may offer and sell, from time to time, shares (the “Shares”) of its common stock, par value $0.001 per share, having an aggregate offering price of up to $50,000,000 through the Sales Agent, acting as agent. Pursuant to the Sales Agreement, sales of the Shares may be made by…

Results of Operations and Financial Condition On May 12, 2025, the Company issued a press release announcing financial results as of and for the quarter ended March 31, 2025. A copy of that press release is attached hereto as Exhibit 99.1 and incorporated herein by reference. The information included in or incorporated by reference into this Item 2.02 (including Exhibit 99.1) is being furnished pursuant to

Termination of a Material Definitive Agreement To the extent required by

The excerpt is incomplete and does not provide sufficient information to determine the nature of the event.

Entry into a Material Definitive Agreement Executive Vice President, Clinical Development On April 14, 2025, the Board of Directors (the “Board”) of CervoMed Inc. (the “Company,” “we” or “us”) appointed Kelly Blackburn, M.H.A., as the Company’s Executive Vice President, Clinical Development, effective April 16, 2025. Ms. Blackburn has previously served as the Company’s Senior Vice President, Clinical Development, since August 2023. Ms. Blackburn’s biography is set forth in our Definitive Prox…

Results of Operations and Financial Condition On March 17, 2025, CervoMed Inc. (the “Company,” “we” or “us”) issued a press release announcing financial results as of and for the quarter and full year ended December 31, 2024. A copy of that press release is attached hereto as Exhibit 99.1 and incorporated herein by reference. The information included in or incorporated by reference into this Item 2.02 (including Exhibit 99.1) is being furnished pursuant to

Results of Operations and Financial Condition On November 12, 2024, CervoMed Inc. (the “Company,” “we” or “us”) issued a press release announcing financial results as of and for the quarter ended September 30, 2024. A copy of that press release is attached hereto as Exhibit 99.1 and incorporated herein by reference. The information included in or incorporated by reference into this Item 2.02 (including Exhibit 99.1) is being furnished pursuant to

Termination of a Material Definitive Agreement As previously disclosed, on July 22, 2022, CervoMed Inc. (the “Company”) entered into an At-The-Market Sales Agreement (the “Sales Agreement”) with BTIG, LLC, as sales agent and/or principal (the “Agent”), pursuant to which the Company was entitled to sell up to an aggregate of $20,000,000 of shares of the Company’s common stock, par value $0.001 (the “Shares”), from time to time through the Agent in “at-the-market offerings” as defined in Rule 4…

Results of Operations and Financial Condition On August 12, 2024, CervoMed Inc. (the “Company,” “we” or “us”) issued a press release announcing financial results as of and for the quarter ended June 30, 2024. A copy of that press release is attached hereto as Exhibit 99.1 and incorporated herein by reference. The information included in or incorporated by reference into this Item 2.02 (including Exhibit 99.1) is being furnished pursuant to

CFO — William Tanner: The CFO is transitioning to a consulting role with a named internal successor (General Counsel) taking over effective immediately, indicating an orderly succession rather than a sudden loss of leadership.

Termination of a Material Definitive Agreement To the extent required by

Entry into a Material Definitive Agreement To the extent required by

Results of Operations and Financial Condition Earnings Press Release On May 15, 2024, CervoMed Inc. (the “Company,” “we” or “us”) issued a press release announcing financial results as of and for the quarter ended March 31, 2024. A copy of that press release is attached hereto as Exhibit 99.1 and incorporated herein by reference. The information included in or incorporated by reference into this Item 2.02 (including Exhibit 99.1) is being furnished pursuant to

Results of Operations and Financial Condition Earnings Press Release On April 1, 2024, CervoMed Inc. (the “Company,” “we” or “us”) issued a press release announcing financial results as of and for the quarter and full year ended December 31, 2023. A copy of that press release is attached hereto as Exhibit 99.1 and incorporated herein by reference. The information included in or incorporated by reference into this Item 2.02 (including Exhibit 99.1) is being furnished pursuant to

Entry into a Material Definitive Agreement On March 28, 2024, CervoMed Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with the purchasers named therein (the “Purchasers”), for the private placement (the “Private Placement”) of an aggregate of 2,532,285 units (the “Units”), each Unit comprised of (i) (A) one share of the Company’s common stock, par value $0.001 per share (the “Common Stock”) or (B) one pre-funded warrant to purchase one share of Co…